| __timestamp | Ascendis Pharma A/S | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 19698000 | 382096000000 |
| Thursday, January 1, 2015 | 40528000 | 345927000000 |
| Friday, January 1, 2016 | 66022000 | 312303000000 |
| Sunday, January 1, 2017 | 99589000 | 325441000000 |
| Monday, January 1, 2018 | 140281000 | 368298000000 |
| Tuesday, January 1, 2019 | 191621000 | 492381000000 |
| Wednesday, January 1, 2020 | 260904000 | 455833000000 |
| Friday, January 1, 2021 | 295867000 | 526087000000 |
| Saturday, January 1, 2022 | 379624000 | 633325000000 |
| Sunday, January 1, 2023 | 413454000 | 729924000000 |
| Monday, January 1, 2024 | 307004000 | 729924000000 |
Unlocking the unknown
In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Takeda Pharmaceutical Company Limited and Ascendis Pharma A/S have demonstrated contrasting yet fascinating trajectories in their R&D investments.
Takeda, a global leader, has consistently invested in R&D, with expenditures growing from 2014 to 2023. By 2023, Takeda's R&D spending reached approximately 730 billion yen, marking a significant increase of nearly 90% from 2014. This steady growth underscores Takeda's commitment to pioneering new treatments and maintaining its competitive edge.
In contrast, Ascendis Pharma A/S, a relatively newer player, has shown a remarkable surge in R&D spending, increasing by over 2,000% from 2014 to 2023. This rapid growth reflects Ascendis' aggressive strategy to innovate and expand its portfolio.
Both companies exemplify the dynamic nature of the pharmaceutical industry, where strategic R&D investments are crucial for future breakthroughs.
Research and Development Expenses Breakdown: Pfizer Inc. vs Takeda Pharmaceutical Company Limited
Research and Development: Comparing Key Metrics for Sanofi and Takeda Pharmaceutical Company Limited
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Amphastar Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and Xencor, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Research and Development Expenses Breakdown: Ascendis Pharma A/S vs Alpine Immune Sciences, Inc.
Research and Development Expenses Breakdown: Ascendis Pharma A/S vs Grifols, S.A.
Ascendis Pharma A/S vs CymaBay Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Ascendis Pharma A/S and Catalyst Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Perrigo Company plc